Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) dropped 6% after the company cut its Q4 sales and full-year EPS guidance, citing lingering fallout from an August cyberattack.

The numbers frame the damage. The eight-day attack cost BSX 300 basis points in sales growth and $0.07 in adjusted EPS. Management is not signaling a quick rebound: it expects a slow recovery and projects 2027 as the trough year. That timeline pushes the earnings reset well beyond the current fiscal year.

Despite the guidance cut, BSX now trades at roughly 13x forward earnings, a relatively low multiple. Interpretation: the market is pricing in a prolonged earnings drag, but the compressed valuation suggests some of that pessimism is already in the stock. Whether 13x represents a floor depends on how credible the 2027 trough call proves.

The pressure is isolated to BSX in this report. Peers MDT and ABT were not cited as affected by the cyberattack or the guidance revision, so the move reads as company-specific rather than a medical device sector repricing. Interpretation: relative-value traders may look at the BSX discount against MDT and ABT, though this report provides no comparative multiples.